Business Wire

Oxford BioDynamics Announces US Launch of Its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for Oncology

OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on its EpiSwitch 3D genomics ...
Morningstar

Oxford Cancer Biomarkers partners with Mira Precision Health to advance its ToxNav® test for predicting patient toxicity to 5FU/capecitabine treatment in the USA

OXFORD, England and MASON, Ohio, June 2, 2025 /PRNewswire/ -- Following the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular ...
WBJournal

Oxford Immunotec requests emergency approval for COVID test

Oxford Immunotec has filed for emergency use authorization for its T-SPOT.COVID test, which detects T cell immune responses to COVID-19, the Marlborough and United Kingdom-based company announced on ...
Hindustan Times

Oxford platform to accelerate Covid-19 tests into use

Jointly led by the University of Oxford and the Manchester University NHS Foundation Trust, the program will put the many tests developed by the life sciences industry to either detect current ...
Yahoo Finance

Oxford BioDynamics Receives Reimbursement Code for EpiSwitch® Prostate Screening (PSE) Test

EpiSwitch PSE boosts the predictive accuracy of current standard PSA test from 55%, to 94% for determining the presence or absence of prostate cancer CPT PLA Code 0433U has been issued to Oxford ...
PharmiWeb

Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men

Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact ...